Kopei 於 2016 年 5 月加入安進，當安進在台灣建立醫藥部門時，領導公司產品的醫療策略、計劃和活動，並推動公司台灣同仁與區域和全球的連結與互動。 到2022 年， Kopei 已加入製藥產業在醫療事務方面擁有超過 13 年的經驗，擔任過醫藥顧問、臨床試驗、科學溝通、在藥廠不同領域的醫藥事務管理等各種角色，在之前已有急診醫學領域11 年的臨床經驗。
在加入安進之前，Kopei 於 2009 年 1 月至 2016 年 4 月在葛蘭素史克工作，擔任台灣地區醫藥顧問與醫藥處長，領導醫療事務、臨床運營和法規事務團隊。他帶領葛蘭素史克台灣完成醫藥互動模式的轉型。擔任醫藥顧問期間，他在台灣葛蘭素史克建立了一個科學溝通的團隊，並負責呼吸、免疫學、皮膚病學、神經科學、腫瘤學、代謝、感染領域提供專業協助。
1996年畢業於國立陽明醫科大學，獲得醫學學士學位，先後在林口長庚醫院接受急診醫學培訓，並在長庚醫院、衛福部基隆醫院、門諾基督教醫院從事急診與臨床治療與照護的工作。
Fatima Ahmad, PharmD is Vice President of Medical Affairs at Castle Creek Biosciences, a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. Previously, she held positions at Spark Therapeutics, a member of the Roche group, including heading the Medical Communications team responsible for leading integrated Medical Communications Strategies across therapeutic areas in Spark’s portfolio of AAV-based investigational gene therapies, as well as serving as Therapeutic Area Leader for hematology. Previously, Fatima spent time at Advaxis Immunotherapies as Senior Director Medical Affairs and at Otsuka Pharmaceuticals, where she held roles of increasing seniority in US and Global Medical Affairs.
Fatima began her industry career at AstraZeneca where she was a Pharmacy intern and subsequently held roles in Medical Information and Medical Communication Science, working across several therapeutic areas including respiratory and oncology. She graduated Magna Cum Laude from Temple University with a PharmD degree, and practiced community pharmacy briefly before transitioning to the pharmaceutical industry. Fatima is passionate about incorporating a patient-centric approach to all aspects of Medical Affairs and is committed to the evolution of Medical Affairs in best serving patients in the era of personalized medicine and novel therapeutic modalities.
